July 31, 2023
Life Sciences | Tea Leaves
  • Johnson & Johnson on Tuesday became the latest drugmaker to go to court to halt Medicare drug price negotiations established by the Inflation Reduction Act. The lawsuit increases the odds that negotiated prices won’t take effect on schedule, beginning in 2026. And the filing in U.S. District Court in Trenton, N.J., also drives up the odds of conflicting legal rulings over the law’s drug price provisions that could prompt the Supreme Court to review the matter. (Article here)